Efficacy as a Vector: The Relative Prevalence and Paucity of Inverse Agonism

Molecular Pharmacology

Volumn 65, Issue 1, 2004, Pages 2-11

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,9 DIETHYL 2 (3 FURYLMETHYL) 2' HYDROXY 6,7 BENZOMORPHAN; G PROTEIN COUPLED RECEPTOR; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; OPIATE ANTAGONIST;

COMPETITIVE INHIBITION; DATA ANALYSIS; DRUG COMPETITION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTENDED TERNARY COMPLEX MODEL; HEALTH SURVEY; HUMAN; INVERSE AGONISM; LIGAND BINDING; MATHEMATICAL MODEL; MOLECULAR MECHANICS; PHENOTYPE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SHORT SURVEY;

ANIMALS; BENZOMORPHANS; GTP-BINDING PROTEINS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; NARCOTIC ANTAGONISTS; RECEPTORS, G-PROTEIN-COUPLED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 1642495639     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.1.2     Document Type: Short Survey

References (158)

1. Allen LF, Lefkowitz RJ, Caron MG, and Cotecchia S (1991) G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the a1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad Sci USA 88:11354-11358.
2. 1D receptors. Neuropsychopharmacology 25:410-422.
3. 35S]-GTPγS binding isotherms. Neuropharmacology 40:57-64.
4. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC (1997) Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385:347-50.
5. Azzi M, Piñeyro G, Pontier S, Parent S, Ansanay H, and Bouvier M (2001) Allosteric effects of G protein overexpression on the binding of β-adrenergic ligands with distinct inverse efficacies. Mol Pharmacol 60:999-1007.
6. Bai Y, Sosnick TR, Mayne L, and Englander SW (1995) Protein folding intermediates: native-state hydrogen exchange. Science (Wash DC) 269:192-197.
7. q11-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 60:1133-1142.
8. 1 receptor antagonists. Eur J Pharmacol 387:R5-R7.
9. Barker EL, RS Westphal RS, Schmidt D, and Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690.
10. 1A receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists. J Biol Chem 272:32979-32987.
11. Beinborn M, Suzanne M, Quinn SM, and Kopin AS (1998) Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. J Biol Chem 273:14146-14151.
12. 2C receptor systems. Mol Pharmacol 55:863-872.
13. Blondel O, Gastineau M, Langlois M, and Fischmeister R (1998) The 5-HT4 receptor antagonist ML10375 inhibits the constitutive activity of human 5-HT4(c) receptor. Br J Pharmacol 125:595-597.
14. i protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55:473-480.
15. Braestrup C, Schmiechen R, Neef G, Nielsen RA, and Petersen EN (1982) Interaction of convulsive ligands with benzodiazepine receptors. Science (Wash DC) 216:1241-1243.
16. 2C receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl-5-pyridyl]carbamoyl]-6-trifluoro methylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem 43:1123-1134.
17. 2C receptor inverse agonists. Bioorg Med Chem Lett 10:1863-1866.
18. 1D receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations. Mol Pharmacol 57:1132-1141.
19. Burgisser E, De Lean A, and Lefkowitz RJ (1982) Reciprocal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide. Proc Natl Acad Sci USA 79:1732-1736.
20. Burstein ES, Spalding TA, and Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312-319.
21. s protein. Mol Pharmacol 56:989-996.
22. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, Joly C, Antonicek H, Bockaert J, Müller T, et al. (2001) BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 59:965-973.
23. Cayla C, Schaak S, Roquelaine C, Gales C, Quinchon F, and Paris H (1999) Homologous regulation of the α2C-adrenoceptor subtype in human hepatocarcinoma, HepG2. Br J Pharmacol 126:69-78.
24. Chen G, Jayawickreme C, Way J, Armour S, Queen K, Watson C, Ignar D, Chen W-J, and Kenakin TP (1999) Constitutive receptor systems for drug discovery. J Pharmacol Toxicol Methods 42:199-206.
25. Chen G, Way J, Armour S, Watson C, Queen K, Jayawrickreme C, Chen W-J, and Kenakin TP (2000) Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 57:125-134.
26. Chen WJ, Armour S, Way J, Chen G, Watson C, Irving P, Cobb J, Kadwell S, Beaumont K, Rimele T, et al. (1997) Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. Mol Pharmacol 52:1164-1175.
27. 2-adrenergic receptor. Mol Pharmacol 50:662-669.
28. 4 receptor antagonists on constitutively active wild-type and mutated receptors. Mol Pharmacol 58:136-144.
29. 1A receptors. Eur J Pharmacol 401:9-15.
30. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
31. Cotecchia S, Lattion AL, Diviani D, and Cavalli A (1995) Regulation of signal-transducing polypeptides. Biochem Soc Trans 23:121-125.
32. Couvineau A and Laburthe M (1985) The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium. J Clin Endocrinol Metab 61:50-58.
33. Cuttita F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, and Minna JD (1985) Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (Lond) 316:823-826.
34. Deakin M and Williams JG (1992) Histamine H2-receptor antagonists in peptic ulcer disease. Drugs 44:709-719.
35. De Lean A, Kilpatrick BF, and Caron MG (1982) Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. Mol Pharmacol 22:290-297.
36. De Lean A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of adenylate cyclase coupled β-adrenergic receptor. J Biol Chem 255 7108-7117.
37. de Ligt RAF, Kourounakis AP, and Ijzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1-12.
38. 2 receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist. Br J Pharmacol 131:1553-1560.
39. Dupré DJ, Le Gouill C, Rola-Pleszczynski M, and Jana J (2001) Inverse agonist activity of selected ligands of platelet-activating factor receptor. J Pharmacol Exp Ther 299:358-365.
40. Durr JA, Hensen J, Ehnis T, and Blankenship MS (2000) Chlorpropamide upregulates antidiuretic hormone receptors and unmasks constitutive receptor signaling. Am J Physiol 278:F799-F808.
41. 2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286:85-90.
42. 2A receptor by site-directed mutagenesis: revelation of inverse activity of antagonists. Ann NY Acad Sci 861:136-139.
43. el Battari A, Martin JM, Luis J, Pouzol O, Secchi J, Marvaldi J, and Pichon J (1988) Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J Biol Chem 263:17685-17689.
44. 1-receptor transgenic mice. Mol Pharmacol 60:712-717.
45. Fathy DB, Leeb T, Mathis SA, and Leeb-Lundberg LM (1999) Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists. J Biol Chem 274:29603-29606.
46. Freissmuth M, Selzer E, and Schutz W (1991) Interactions of purified bovine brain A1-adenosine receptors with G-proteins. Biochem J 275:651-656.
47. 1d-adrenoceptors. FEBS Lett 443:277-281.
48. Gardella TJ, Luck MD, Jensen GS, Schipani E, Potts JT Jr, and Juppner H (1996) Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 137:3936-3941.
49. 1B receptor inverse agonist 1′-methyl-5-[[2′ -methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6, 7-tetrahydro-spiro[furo[2,3-f]indole-3,4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem 41:1218-1235.
50. Geras-Raaka E, Varma A, Ho H, Clark-Lewis I, and Gershengorn MC (1998) Human interferon-γ-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J Exp Med 188:405-408.
51. 2 adrenergic receptor. J Biol Chem 276: 24433-24436.
52. Gotze K and Jacobs KH (1994) Unoccupied beta-adrenoceptor-induced adenylyl cyclase stimulation in turkey erythrocyte membranes. Eur J Pharmacol 268:151-158.
53. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, and Brenneman DE (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 257:959-966.
54. Griffon N, Pilon C, Sautel F, Schwartz JC, and Sokoloff P (1996) Antipsychotics with inverse agonist activity at dopamine receptors. J Neural Transm 103:1163-1175.
55. Grimberg H, Zaltsman I, Lupu-Meiri M, Gershengorn MC, and Oron Y (1999) Inverse agonist abolishes desensitization of a constitutively active mutant of thyrotropin-releasing hormone receptor: role of cellular calcium and protein kinase C. Br J Pharmacol 126:1097-1106.
56. 2C receptor antagonists. J Biol Chem 271:22591-22597.
57. 1B-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 363:34-39.
58. 2C receptor. J Neurochem 69:1138-1144.
59. 2C receptor. Ann NY Acad Sci 861:140-145.
60. Herrick-Davis K, Grinde E, and Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226-232.
61. Hoshohata K, Burkey TH, Alfaro-Lopez J, Hruby VJ, Roeke WR, and Yamamura HI (1999) (2S,3R)TMT-L-Tic-OH is a potent inverse agonist at the δ-opioid receptor. Eur J Pharmacol 380:R9-R10.
62. 4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett 377:275-279.
63. 2A-adrenoceptors. Mol Pharmacol 53:963-968.
64. Jeng M-F, Englander SW, Elove GA, Wand AJ, and Roder H (1991) Structural description of acid-denatured cytochrome c by hydrogen exchange and 2D NMR. Biochemistry 29:10433-10437.
65. Julius D, Macdermott AB, Axel R, and Jessell TM (1988) Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. Science (Wash DC) 241:558-564.
66. Kenakin TP (1995) Pharmacological proteus? Trends Pharmacol Sci 16:256-258.
67. Kenakin TP (1997) Protean agonists: keys to receptor-active states? Ann NY Acad Sci 812:116-195.
68. Kenakin TP (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:596-611.
69. Kenakin TP (2002a) Efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
70. Kenakin TP (2002b) Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 1:103-109.
71. Kenakin TP (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354.
72. Kenakin TP and Onaran O (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23:275-280.
73. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooji PPM, Ausema L, Lamberts JS, and Reubi JC (1989) Localization of endocrine-related tumors with radiodinated analogue of somatostatin. Lancet 8632:242-244.
74. Kroog GS, Jensen RT, and Battey JF (1995) Mammalian bombesin receptors. Med Res Rev 15:389-417.
75. LaBarre M, Butterworth J, St-Onge S, Payza K, Schmidhammer H, Salvadori S, Balboni G, Guerrini R, Bryant SD, Lazarus LH, et al. (2000) Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue. Eur J Pharmacol 406: R1-R3.
76. Labrecque J, Fargin A, Bouvier M, Chidiac P, and Dennis M (1995) Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol Pharmacol 48:150-159.
77. Lamberts SW, Bakker WH, Reubi J, and Krenning EP (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246-1249.
78. Landsman RS, Makriyannis A, Deng HF, Consroe P, Roeske WR, and Yamamura HI (1998) AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci 62:PL109-PL113.
79. Lee M, Jensen RT, Bepler G, Korman LY, and Moody TW (1990) Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels. Peptides 11:1205-1210.
80. 1β-adrenoceptor by ligands that act as inverse agonists. Biochem J 325:733-739.
81. Leeb-Lundberg M, Mathis SA, and Herzig MC (1994) Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem 269:25970-25973.
82. Li J, Chen C, Huang P, and Liu-Chen L-Y (2001) Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat μ-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol 60:1064-1075.
83. 5]enkephalin. J Biol Chem 276:37779-37786.
84. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR, et al. (1990) Two G-protein oncogenes in human endocrine tumors. Science (Wash DC) 249:655-659.
85. 2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol 50:1479-1486.
86. MacLennan SJ, Reynen PH, Kwan J, and Bonhaus DW (1998) Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124:619-622.
87. 13,14] Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Cancer Res 51:1798-1802.
88. 35S] binding. J Pharmacol Exp Ther 285:119-126.
89. Maruno K, Yamaguchi K, Abe K, Suzuki M, Sijo N, Mishima Y, Yanaihara N, and Shimosato Y (1989) Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 49:629-632.
90. 1D-adrenoceptors by agonists and inverse agonists. Mol Pharmacol 57:659-666.
91. Meschle JP, Kraichely DM, Wilken GH, and Howlett AC (2000) Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methyoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB1 cannabinoid receptor. Biochem Pharmacol 60:1315-1323.
92. Mewes T, Dutz S, Ravens U, and Jakobs KH (1993) Activation of calcium currents in cardiac myocytes by empty β-adrenoceptors. Circulation 88:2916-2922.
93. Millan MJ, Gobert A, Audinot V, Dekeyne A, and Newman-Tancredi A (1999) Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)(1B) receptors to G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacology 21:61S-67S.
94. Milligan G and Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474.
95. Milne JS, Xu Y, Mayne LC, and Englander SW (1999). Experimental study of the protein folding landscape: unfolding reactions in cytochrome c. J Mol Biol 290: 811-822.
96. Monczor F, Legnazzi BL, Rivera E, and Davio C (1998) Tioditine, a classical H2-antaognist, presents characteristics of an inverse agonist in U937 cell line. Inflamm Res 47 (Suppl 1):S42-S43.
97. Moody TW, Zia F, Draque M, Brenneman DE, Fridkin M, Davidson A, and Gozes I (1993) A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci USA 90:4345-4349.
98. 2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett 441:470-475.
99. 3 receptors regulates histamine neurons in brain. Nature (Lond) 408:860-864.
100. Mullaney I, Carr IC, and Milligan G (1996) Analysis of inverse agonism at the δ-opioid receptor after expression in Rat 1 fibroblasts. Biochem J 315:227-234.
101. Murrin CL, Gerety M, Happe HK, and Bylund DB (2000) Inverse agonism at α2-adrenoceptors in native tissue. Eur J Pharmacol 398:185-191.
102. Nagaraja S, Iyer S, Liu X, Eichberg J, and Bond RA (1999) Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic beta2-adrenoceptor activation. Br J Pharmacol 127:1099-1104.
103. 1B receptor/G-protein stoichiometry. Mol Pharmacol 58:1042-1049.
104. Newman-Tancredi A, Conte C, Chaput C, Spedding M, and Millan MJ (1997a) Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br J Pharmacol 120:737-739.
105. Newman-Tancredi A, Conte C, Chaput C, Verriele L, and Millan MJ (1997b) Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacology 36:451-459.
106. Nijenhuis WA, Oosterom J, and Adan RAH (2001) AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 15:164-171.
107. 2 receptor is antagonized by R(-)-n-propylnorapo-morphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology 15:53-61.
108. Nwolko CU, Smith JTL, Gavey GC, Sawyer AM, and Pounder RE (1990) Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 4:29-45.
109. 2-receptor blockade. Gut 32:1455-1460.
110. O'Dorisio MS, Fleshman DJ, Qualman SJ, and O'Dorisio TM (1992) Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regulat Peptides 37:213-236.
111. Onaran HO and Costa T (1997) Agonist efficacy and allosteric models of receptor action. Ann NY Acad Sci 812:98-115.
112. Onaran HO, Scheer A, Cotechhia S, and Costa T (2000) A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor, in The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology (Kenakin TP and Angus JA eds) vol 148, pp 217-280, Springer, New York.
113. Pagano A, Rüegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezèau L, Carroll F, Pin J-P, et al. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
114. Palvimaki E-P, Majasuo H, Kuoppamäki M, Männistö PT, Syvälahti E, Jarmo P, and Hietala J (1998) Deramciclane, a putative anxiolytic drug is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl) 136:99-104.
115. 1B/D Receptor Antagonists. Gen Pharmacol 29:293-303.
116. Pauwels PJ (2002) Evidence for protean agonism of RX 831003 at α2A-adrenoceptors by co-expression with different Gα protein subunits. Neuropharmacology 42:855-863.
117. Pauwels PJ, Gouble A, and Wurch T (1999) Constitutive 5-hydroxytryptamine 1B receptor activation. Biochem J 343:435-442.
118. α protein subunits. Neuropharmacology 42:855-863.
119. 1B/D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 36:499-512.
120. αo protein coexpression: evidence for inverse agonism. J Pharmacol Exp Ther 292: 654-663.
121. Pauwels PJ, Wurch T, Palmier C, and Colpaert FC (1998) Pharmacological analysis of G-protein activation mediated by guinea-pig recombinant 5-HT1B receptors in C6-glial cells: similarities with the human 5-HT1B receptor. Br J Pharmacol 123:51-62.
122. Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, Barth F, Le Fur G, and Casellas P (1999) SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther 288:582-589.
123. Pozvek G, Hilton JM, Quiza M, Houssami S, and Sexton PM (1997) Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. Mol Pharmacol 51:658-665.
124. Richard F, Barroso S, Martinez J, Labbé-Jullié C, and Kitabgi P (2001) Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol 60:1392-1398.
125. i: precoupling and constitutive activity. Mol Pharmacol 56:1014-1024.
126. Rosenkilde MM, Kledal TN, Bräuner-Osborne H, and Schwartz TW (1999) Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem 274:956-961.
127. Rosenkilde MM and Schwartz TW (2000) Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. Mol Pharmacol 57:602-609.
128. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126:665-672.
129. 1b-adrenergic receptor subtypes. Mol Pharmacol 56:858-866.
130. Samama P, Pei G, Costa T, Cotecchia S, and Lefkowitz RJ (1994) Negative antagonists promote an inactive conformation of the β2-adrenergic receptor. Mol Pharmacol 45:390-394.
131. Schipani E, Kruse K, and Juppner H (1995) A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science (Wash DC) 268:98-100.
132. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 366:381-416.
133. Serre V, Dolci W, Schaerer E, Scrocchi L, Drucker D, Efrat S, and Thorens B (1998) Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and β-cell glucose competence. Endocrinology 139:4448-4454.
134. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, and Ferrara P (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 65:627-635.
135. 1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol 53:886-893.
136. Smit MJ, Leurs R, Alewijnse AE, Blauw J, Amerongen GPV, Vandevrede Y, Roovers E, and Timmerman H (1996) Inverse agonism of histamine H-2 antagonists accounts for up-regulation of spontaneously active histamine H-2 receptors. Proc Natl Acad Sci USA 93:6802-6807.
137. 1 melatonin receptor partial agonists, antagonists, and putative Inverse agonists. J Med Chem 41:3624-3634.
138. Spiegel AM (1996) Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol 58:143-170.
139. Spiegel AM, Weinstein LS, and Shenker A (1993) Abnormalities in G-protein-coupled signal transduction pathways in human disease. J Clin Investig 92:1119-1125.
140. Sreedham SP, Robichon A, Peterson KE, and Goetzl EJ (1991) Cloning and expression of the human vasoactive intestinal peptide receptor. Proc Natl Acad Sci USA 88:4986-4990.
141. 35S]GTPγS binding. Eur J Pharmacol 320:267-275.
142. Stevens PA and Milligan G (1998) Efficacy of inverse agonists in cells overexpressing a constitutively active beta2-adrenoceptor and type II adenylyl cyclase. Br J Pharmacol 123:335-343.
143. Svoboda M, De Neef P, Tastenoy M, and Christophe J (1988) Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2 J. Eur J Biochem 176:707-713.
144. 35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther 283:1276-1284.
145. Thomas DR, Gittins SA, Collin LL, Middlemiss DN, Riley G, Hagan J, Gloger I, Ellis CE, Forbes IT, and Brown AM (1998) Functional characterisation of the human cloned 5-HT7 receptor (long form): antagonist profile of SB-258719. Br J Pharmacol 124:1300-1306.
146. Tian WN, Duzic E, Lanier SM, and Deth RC (1994) Determinants of α2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol Pharmacol 45:524-531.
147. 1 receptors. Eur J Pharmacol 331:275-284.
148. Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Nierderle B, Scheithauer W, and Valent P (1994) Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 54:690-700.
149. 2A-adrenergic receptor. Mol Pharmacol 59:532-542.
150. Weinstein LS, Gejman PV, De Mazancourt P, American N, and Spiegel AM (1990) A heterozygous 4-bp deletion mutation in the Gsa gene (GNAS1) in a patient with Albright hereditary osteodystrophy. Genomics 13:1319-1321.
151. Wenzel-Seifert K, Hurt CM, and Seifert R (1998) High constitutive activity of the human formyl peptide receptor. J Biol Chem 273:24181-24189.
152. Westphal RS and Sanders-Bush E (1994) Reciprocal binding properties of 5-hydroxy-tryptamine type 2C receptor agonists and inverse agonist. Mol Pharmacol 46:937-942.
153. 3 antagonists. J Pharmacol Exp Ther 299:908-814.
154. 2-receptor antagonists. Dig Dis Sci 35:976-983.
155. Wood PL, Loo P, Braunwalder A, Yokoyama N, and Cheney DL (1984) In vitro characterization of benzodiazepine receptor agonists, antagonists, inverse agonists and agonist/antagonists. J Pharmacol Exp Ther 231:572-576.
156. 3 receptors. Eur J Pharmacol 453:33-41.
157. Zaki PA, Keith DE Jr, Thomas JB, Carroll FI, and Evans CJ (2001) Agonist-, antagonist-, and inverse agonist-regulated trafficking of the δ-opioid receptor correlates with, but does not require, G protein activation. J Pharmacol Exp Ther 298:1015-1020.
158. Zhu J, Taniguchi T, Takauji R, Suzuki F, Tanaka T, and Muramatsu I (2000) Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor. Br J Pharmacol 131:546-552.